Arthur Mercurio

Arthur Mercurio is a Professor at the University of Massachusetts Chan Medical School (UMMS) and holds roles at the T.H. Chan School of Medicine and multiple graduate programs at Morningside Graduate School of Biomedical Sciences. His academic journey includes a B.S. in Biochemistry from Rutgers University (1975) and a Ph.D. in Cell Biology from Columbia University (1981). He has been a faculty member at Harvard Medical School and later held leadership positions at UMMS, including Vice Chairman of the Department of Cancer Biology and Interim Chair.

Dr. Mercurio's research focuses on translational cancer cell biology, particularly mechanisms driving tumor initiation and progression in carcinomas. Key areas include integrin regulation (α6β1/β4), VEGF/Neuropilin signaling in tumor stem cells, and estrogen receptor-mediated differentiation. His lab has identified critical roles for integrins and VEGF pathways in aggressiveness, metastasis, and therapeutic resistance.

Notable contributions include discovery of the β4 integrin's role in carcinoma progression, VEGF/NRP2 signaling's impact on tumor initiation, and ERβ's regulation of epithelial differentiation. His work bridges biochemical mechanisms and clinical outcomes, with implications for therapies targeting ferroptosis, immunotherapy, and resistance mechanisms.

• Scientific Awards: American Cancer Society Junior Faculty Award (undated), American Cancer Society Faculty Research Award (undated), Honorary Professor at University of Copenhagen (undated).
• Grants/Research Funding: Omitted due to lack of explicit funding details in text.

Dr. Mercurio's labs and affiliations include Bioinformatics and Integrative Biology programs at UMMS, and collaborations across multiple biomedical disciplines. His work emphasizes interdisciplinary approaches to combat aggressive cancers through molecular and cellular mechanisms.